The Moving Average Convergence Divergence (MACD) for PYPD turned positive on October 22, 2026. Looking at past instances where PYPD's MACD turned positive, the stock continued to rise in 43 of 51 cases over the following month. The odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on PYPD as a result. In 107 of 128 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
PYPD moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where PYPD advanced for three days, in 180 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for PYPD crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PYPD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
PYPD broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PYPD entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. PYPD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.752) is normal, around the industry mean (2.974). P/E Ratio (-4.405) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PYPD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SYRE moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 66 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 36 of 42 cases over the following month. The odds of a continued upward trend are 86%.
Following a +9.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 259 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for SYRE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.147) is normal, around the industry mean (2.974). P/E Ratio (-51.603) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PYPD | SYRE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 86 Overvalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 96 | |
PRICE GROWTH RATING 1..100 | 38 | 35 | |
P/E GROWTH RATING 1..100 | 56 | 42 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYRE's Valuation (5) in the Pharmaceuticals Major industry is significantly better than the same rating for PYPD (86) in the null industry. This means that SYRE’s stock grew significantly faster than PYPD’s over the last 12 months.
SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PYPD (100) in the null industry. This means that SYRE’s stock grew similarly to PYPD’s over the last 12 months.
SYRE's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as PYPD (100) in the null industry. This means that SYRE’s stock grew similarly to PYPD’s over the last 12 months.
SYRE's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as PYPD (38) in the null industry. This means that SYRE’s stock grew similarly to PYPD’s over the last 12 months.
SYRE's P/E Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as PYPD (56) in the null industry. This means that SYRE’s stock grew similarly to PYPD’s over the last 12 months.
| PYPD | SYRE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 84% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 84% | 1 day ago 86% |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 83% | 1 day ago 88% |
| Advances ODDS (%) | 1 day ago 82% | 1 day ago 87% |
| Declines ODDS (%) | 14 days ago 84% | 5 days ago 87% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PYPD’s FA Score shows that 0 FA rating(s) are green while SYRE’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PYPD’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).
PYPD (@Biotechnology) experienced а +12.04% price change this week, while SYRE (@Biotechnology) price change was +8.36% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.36%. For the same industry, the average monthly price growth was -13.16%, and the average quarterly price growth was -14.28%.
PYPD is expected to report earnings on Nov 11, 2026.
SYRE is expected to report earnings on Nov 03, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor tells us that PYPD and AMLX have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PYPD and AMLX's prices will move in lockstep.
| Ticker / NAME | Correlation To PYPD | 1D Price Change % | ||
|---|---|---|---|---|
| PYPD | 100% | +9.07% | ||
| AMLX - PYPD | 29% Poorly correlated | +4.47% | ||
| SYRE - PYPD | 29% Poorly correlated | +6.60% | ||
| TSHA - PYPD | 28% Poorly correlated | +5.99% | ||
| INM - PYPD | 28% Poorly correlated | N/A | ||
| FENC - PYPD | 28% Poorly correlated | +4.63% | ||
More | ||||
A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ORKA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ORKA could also see price increases.
| Ticker / NAME | Correlation To SYRE | 1D Price Change % | ||
|---|---|---|---|---|
| SYRE | 100% | +6.60% | ||
| ORKA - SYRE | 51% Loosely correlated | +6.07% | ||
| PHVS - SYRE | 45% Loosely correlated | +1.30% | ||
| BEAM - SYRE | 45% Loosely correlated | +4.67% | ||
| IMVT - SYRE | 44% Loosely correlated | +2.52% | ||
| PMN - SYRE | 44% Loosely correlated | +20.25% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TSXU | 49.98 | 2.24 | +4.69% |
| Direxion Daily Semiconductors Top 5 Bull 2X ETF (TSXU) | |||
| MTUM | 299.53 | 4.97 | +1.69% |
| iShares MSCI USA Momentum Factor ETF (MTUM) | |||
| JDVI | 39.38 | 0.32 | +0.83% |
| John Hancock Disciplined Value International Select ETF (JDVI) | |||
| PBOC | 31.64 | 0.11 | +0.36% |
| PGIM S&P 500 Buffer 20 ETF - October (PBOC) | |||
| GUSH | 49.83 | -2.42 | -4.63% |
| Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X ETF (GUSH) | |||